#Canada #Toronto #Stem Cell Technology #diabetes treatment #Visionary Holdings

Visionary Holdings Advances Diabetes Treatment with Major Licensing Agreement

In a landmark development, Visionary Holdings Inc. (Nasdaq: GV) has announced a groundbreaking global licensing agreement that could reshape the treatment landscape for diabetes patients. On October 13, 2025, the multinational technology firm revealed that its subsidiary, Visionary Holdings (Asia) Limited, has forged a strategic alliance with Jiangsu Yike Regenerative Medicine Co., Ltd. This partnership grants GV exclusive worldwide rights to utilize Yike's advanced stem cell technology, which has shown remarkable promise in addressing both Type 1 and Type 2 diabetes.

Diabetes remains a pressing global health challenge, affecting over 540 million adults and presenting a treatment market exceeding USD 150 billion. Current therapeutic options primarily focus on managing blood glucose levels and delaying complications rather than offering long-term solutions or cures. However, the collaboration between GV and Yike is poised to change that narrative, presenting a significant opportunity for transformative patient outcomes.

Yike's proprietary regenerative medicine technology boasts a comprehensive system targeting diabetes via stem cell therapy, cellular rejuvenation, and biological repair processes. Clinical trials have suggested that this innovative approach could lead to long-term remission – and potentially, a complete cure – by restoring pancreatic islet function among diabetic patients.

The collaborative effort aims to harness Yike's advanced platform to expedite the commercialization and clinical application of these cutting-edge treatments. Key areas of focus will include stem cell therapies, along with the establishment of protocols for cell preparation, storage, and clinical application. Through this agreement, GV will leverage its global commercialization network and expertise to boost the efficacy and reach of these innovative technologies in the market.

This partnership is not solely about technological innovation; it also proposes a revenue-sharing structure that aligns the interests of both GV and Yike. As revenue will be generated based on product sales and technological licensing, this arrangement allows each entity to capitalize on their strengths—Yike’s technological prowess and GV's expansive market reach and brand operations.

CEO of Visionary Holdings, Xiyong Hou, articulated the significant implications of this partnership, stating, "This global license for Yike's stem cell technology marks a major milestone in GV's global health strategy. Our joint efforts have the potential to transform diabetes treatment, significantly improving health outcomes for millions worldwide."

Looking ahead, GV and Yike plan to deepen their collaboration across product research and development, clinical validation, and market expansion efforts while also advocating for global certification standards for regenerative medical products. This concerted approach promises to establish a robust foundation for GV's leadership in the fast-evolving medical technology space.

Visionary Holdings Inc., headquartered in Toronto, Canada, continues to diversify its portfolio, focusing on innovative solutions within healthcare and technology sectors. With this alliance, the company positions itself not only as a leader in emerging health technologies but as a pivotal player in shaping the future landscape of diabetes treatment—and potentially, other medical realms.

Through strategic partnerships like the one with Yike, GV is contributing to a brighter future for patients seeking treatments that can offer more than just management of their conditions, aiming for genuine solutions that restore health and well-being. As this partnership unfolds, it will be crucial to watch how these developments progress within the rapidly changing landscape of medical innovation.